Access to COVID-19 Diagnostics
Testing the right people, at the right moment and with the right tool is essential for the Covid-19 pandemic management. Both the Swiss international cooperation and the Swiss pharmaceutical sector have a long-standing experience and interest in supporting R&D, access and manufacturing of diagnostics.. The Foundation for Innovative New Diagnostics (FIND) is leading the global effort (ACT-A Dx Partnership) in the development of affordable COVID-19 diagnostics and local manufacturing capacity for and in LMICs.
Paese/Regione | Tema | Periodo | Budget |
---|---|---|---|
Mondo |
Sanità Impiego & sviluppo economico
Malattie infettive
Rafforzamento dei sistemi sanitari Politica commerciale & sistema de mercato |
01.09.2020
- 31.12.2023 |
CHF 26’000’000
|
- Other international or foreign NGO North
- Foundation for Innovative New Diagnostics (FIND)
-
Settore in base alle categorie del Comitato di Aiuto allo sviluppo (DAC) dell'OCSE SALUTE
SALUTE
POLITICHE COMMERCIALI E REGOLAMENTAZIONE
Sotto-Settore in base alle categorie del Comitato di Aiuto allo sviluppo (DAC) dell'OCSE Controllo delle malattie infettive
Politica sanitaria e gestione amministrativa
Politica commerciale e gestione amministrativa
Tipo di aiuto Contributo al progetto e al programma
Numero del progetto 7F10613
Contesto |
|
|
Obiettivi | Accelerate universal and equitable access to safe, quality and effective COVID-19 diagnostics | |
Gruppi target |
- Researchers and clinicians in LMICs. - The global research and development community for COVID-19. - Manufacturers, regulators and procurement agencies (UNICEF, Global - Patients and population at high risk for COVID-19. |
|
Effetti a medio termine |
1. Local manufacturing capacity enhanced to meet regional demand 2. Countries are able to utilize digital solutions as part of their COVID response |
|
Risultati |
Risultati principali attesi: - Research and Development: Accelerate development and availability of high performing, affordable rapid diagnostic tools, and create - Market readiness: Implement market shaping interventions to - Supply: Identification of supply availability, demand aggregation and ensure efficient logistics and delivery. - Country capacity building: Strengthen health systems and build Risultati fasi precedenti: Not applicable. This is a new proposal. |
|
Direzione/Ufficio responsabile |
DSC |
|
Credito |
Cooperazione allo sviluppo |
|
Partner del progetto |
Partner contrattuale ONG internazionale o straniera Altri partner Governments, NGOs, private sector |
|
Coordinamento con altri progetti e attori | The ACT-A initiative on therapeutics (Wellcome Trust) and vaccine (Gavi), the WHO Blue Print Project. The Global Fund, WHO | |
Budget | Fase in corso Budget Svizzera CHF 26’000’000 Budget svizzero attualmente già speso CHF 25’999’550 | |
Fasi del progetto |
Fase 1 01.09.2020 - 31.12.2023 (Completed) |